CTOs on the Move


 
  • Number of Employees:
  • Annual Revenue:

  • ,

Executives

Name Title Contact Details

Similar Companies

SISU

Sisu is an industry thought leader in the fields of robotics and automation. We take on complex engineering problems that often involve adopting or inventing new technologies. We are disrupting the cinema, industrial knife sharpening, welding, and other industries. With robots that are easy to program, its no wonder that we are one of the fastest-growing cinema robotics companies in the world! We provide a fast-paced and exciting work environment, built on values of hard work and family, attracting top talent from across the country. Sisu is located in beautiful Austin Texas and serves customers in the United States and around the world. Sisu is a Kuka Robotics System Partner and an alliance partner with National Instruments.

The Fusion Syndicate

Unlock Your Business Creativity with AI-accelerated Content Productivity. We leverage our BPR know-how and unique bottled marketing and operation expertise to help business leaders receive deeper insights using Gen AI. Embrace the AI-assisted revolution with TFS custom deep prompts, GPTs for ChatGPT Team, and individualized consulting to improve efficiency, effectiveness, and quality. Our team combines decades of expertise with a pioneering spirit. We understand AI is a transformative technology, but we also recognize the irreplaceable value of human insight and oversight. Our offerings blend the strengths of people and machines through prompt engineering, consulting, and subscription-based access to our AI knowledge base. Depending on your specific needs, one of our experts will lead your project. Contact us at info@TheFusionSyndicate.com today to learn more. ***Privacy Statement*** We value your privacy and are committed to keeping your personal information secure. We will never sell your data to a third party and will only use it to contact you regarding our services. Rest assured that we will handle your information with the utmost care and confidentiality.

Atlas Battery Limited

Atlas Battery Limited was incorporated as a public limited Company on October 19, 1966 and its shares are listed on Karachi and Lahore Stock Exchanges in Pakistan. The Company is engaged in manufacture and sales of AGS brand, automotive and motorcycle batteries. The Company has joint venture with GS Yuasa International. Atlas Battery Limited pioneered the manufacture of dry charged Hard Rubber batteries in Pakistan. The company has always been at the vanguard of development in the automotive industry in Pakistan making great strides in the fields research and development. The brand has, over the years, earned a solid reputation as a product of latest Japanese technology with consistently high levels of performance and reliability.

IMUNON

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.